MARKET

TNGX

TNGX

Tango Therapeutics Inc
NASDAQ
30.11
-1.45
-4.59%
Opening 10:56 06/10 EDT
OPEN
31.65
PREV CLOSE
31.56
HIGH
31.66
LOW
29.42
VOLUME
3.17M
TURNOVER
--
52 WEEK HIGH
32.79
52 WEEK LOW
3.770
MARKET CAP
4.36B
P/E (TTM)
-36.4396
1D
5D
1M
3M
1Y
5Y
1D
BUZZ-U.S. STOCKS ON THE MOVE-Cracker Barrel, Tango Therapeutics, Chewy
Reuters · 5h ago
BUZZ-Tango Therapeutics rises premarket after upsized $600 mln equity raise
Reuters · 6h ago
Tango Therapeutics 18.2M share Secondary priced at $30.00
TipRanks · 8h ago
Tango Therapeutics prices upsized $600M public offering at $30/share
Seeking Alpha · 11h ago
Tango Therapeutics Prices $600 Mln Upsized Offering Of Shares And Pre-Funded Warrants
NASDAQ · 11h ago
*Tango Therapeutics Expects Gross Proceeds of About $600M From Offering >TNGX
Dow Jones · 15h ago
*Tango Therapeutics Offering 18.2M Public Offering Shares at $30 Each >TNGX
Dow Jones · 15h ago
*Tango Therapeutics Offering Prefunded Warrants to Purchase Up to 1.8M Shares at $29.999 Each >TNGX
Dow Jones · 15h ago
More
About TNGX
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company's novel small molecules are designed to be selectively active in cancer cells with specific genetic alterations, killing those cancer cells while sparing normal cells. The Company is focused on clinical development of two methylthioadenosine phosphorylase (MTAP)-deleted selective PRMT5 inhibitors: vopimetostat (TNG462) for non-CNS cancers, both as a monotherapy and in combination with RAS inhibitors, and TNG456, brain-penetrant protein arginine methyltransferase 5 (PRMT5) inhibitor, for CNS cancers, including glioblastoma (GBM). Its TNG260 is a first-in-class Co-repressor of the Repressor Element-1 Silencing Transcription (CoREST) inhibitor, which in preclinical studies reversed the immune evasion effect of STK11 loss-of-function mutations.

Webull offers Tango Therapeutics Inc stock information, including NASDAQ: TNGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TNGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TNGX stock methods without spending real money on the virtual paper trading platform.